148 related articles for article (PubMed ID: 34366886)
1. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease.
Li N; Xie G; Zhou B; Qu A; Meng H; Liu J; Wang G
Front Physiol; 2021; 12():696163. PubMed ID: 34366886
[No Abstract] [Full Text] [Related]
2. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
Zhang L; Wu X; Li X; Chang X; Ding X; Wang Q; Jiang T; Wang G; Liu J
Acta Diabetol; 2023 Jul; 60(7):971-979. PubMed ID: 37079136
[TBL] [Abstract][Full Text] [Related]
3. Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease.
Chen X; Sun X; Shen T; Chen Q; Chen S; Pang J; Mi J; Tang Y; You Y; Xu H; Ling W
Free Radic Biol Med; 2020 Nov; 160():191-198. PubMed ID: 32810635
[TBL] [Abstract][Full Text] [Related]
4. Association of Serum Adropin Concentrations with Diabetic Nephropathy.
Hu W; Chen L
Mediators Inflamm; 2016; 2016():6038261. PubMed ID: 27546995
[TBL] [Abstract][Full Text] [Related]
5. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease.
Sayın O; Tokgöz Y; Arslan N
J Pediatr Endocrinol Metab; 2014 May; 27(5-6):479-84. PubMed ID: 24468600
[TBL] [Abstract][Full Text] [Related]
6. Association of Uric Acid to Creatinine Ratio with Metabolic Dysfunction-Associated Fatty Liver in Non-Obese Individuals Without Type 2 Diabetes Mellitus.
Liu J; Wang C; Wang Y; Yao S
Diabetes Metab Syndr Obes; 2024; 17():131-142. PubMed ID: 38222031
[TBL] [Abstract][Full Text] [Related]
7. Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus.
Choi HN; Yim JE
J Cancer Prev; 2018 Dec; 23(4):191-196. PubMed ID: 30671402
[TBL] [Abstract][Full Text] [Related]
8. Serum adropin level and ENHO gene expression in systemic sclerosis.
Yolbas S; Kara M; Yilmaz M; Aydin S; Koca SS
Clin Rheumatol; 2016 Jun; 35(6):1535-40. PubMed ID: 27079850
[TBL] [Abstract][Full Text] [Related]
9. Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy.
Dang SW; Gao L; Li YJ; Zhang R; Xu J
Front Med (Lausanne); 2023; 10():1216412. PubMed ID: 37828942
[TBL] [Abstract][Full Text] [Related]
10. Adropin deficiency worsens HFD-induced metabolic defects.
Chen S; Zeng K; Liu QC; Guo Z; Zhang S; Chen XR; Lin JH; Wen JP; Zhao CF; Lin XH; Gao F
Cell Death Dis; 2017 Aug; 8(8):e3008. PubMed ID: 28837146
[TBL] [Abstract][Full Text] [Related]
11. ENHO gene expression and serum adropin level in rheumatoid arthritis and systemic lupus erythematosus.
Yolbas S; Kara M; Kalayci M; Yildirim A; Gundogdu B; Aydin S; Koca SS
Adv Clin Exp Med; 2018 Dec; 27(12):1637-1641. PubMed ID: 30141839
[TBL] [Abstract][Full Text] [Related]
12. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study.
Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
Front Endocrinol (Lausanne); 2022; 13():942412. PubMed ID: 36133303
[TBL] [Abstract][Full Text] [Related]
13. [Associations between serum GDF15 and glycolipid metabolism disorder in metabolic associated fatty liver patients].
Li X; Yu XM; Li EH; Chen PH; Zheng LM; Zhang S
Zhonghua Nei Ke Za Zhi; 2023 Aug; 62(8):987-992. PubMed ID: 37528037
[No Abstract] [Full Text] [Related]
14. Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease.
Jia J; Liu R; Wei W; Yu F; Yu X; Shen Y; Chen C; Cai Z; Wang C; Zhao Z; Wang D; Yang L; Yuan G
Front Physiol; 2021; 12():762242. PubMed ID: 34975521
[No Abstract] [Full Text] [Related]
15. Decreased Serum Osteocalcin is an Independent Risk Factor for Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes.
Wang YJ; Jin CH; Ke JF; Wang JW; Ma YL; Lu JX; Li MF; Li LX
Diabetes Metab Syndr Obes; 2022; 15():3717-3728. PubMed ID: 36471670
[TBL] [Abstract][Full Text] [Related]
16. The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: a cross‑sectional study.
Wei W; Liu H; Qiu X; Zhang J; Huang J; Chen H; Qiu S; Lin R; Li S; Tu M
Diabetol Metab Syndr; 2022 Feb; 14(1):27. PubMed ID: 35135590
[TBL] [Abstract][Full Text] [Related]
17. Adropin: An endocrine link between the biological clock and cholesterol homeostasis.
Ghoshal S; Stevens JR; Billon C; Girardet C; Sitaula S; Leon AS; Rao DC; Skinner JS; Rankinen T; Bouchard C; Nuñez MV; Stanhope KL; Howatt DA; Daugherty A; Zhang J; Schuelke M; Weiss EP; Coffey AR; Bennett BJ; Sethupathy P; Burris TP; Havel PJ; Butler AA
Mol Metab; 2018 Feb; 8():51-64. PubMed ID: 29331507
[TBL] [Abstract][Full Text] [Related]
18. Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure.
Berezina TA; Obradovic Z; Boxhammer E; Berezin AA; Lichtenauer M; Berezin AE
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983232
[TBL] [Abstract][Full Text] [Related]
19. Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients.
Grzegorzewska AE; Niepolski L; Mostowska A; Warchoł W; Jagodziński PP
Life Sci; 2016 Sep; 160():41-46. PubMed ID: 27449397
[TBL] [Abstract][Full Text] [Related]
20. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
